Literature DB >> 29357116

The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function.

Saige L Pompura1,2, Margarita Dominguez-Villar2.   

Abstract

The PI3K/AKT signaling pathway is an essential node in mammalian cells that controls cell growth, migration, proliferation, and metabolism. During the last decade, a number of works have demonstrated an important role for the PI3K/AKT pathway in regulatory T cell development, function, and stability. This review summarizes our current knowledge of how the PI3K/AKT pathway regulates thymic and peripheral Treg generation and function, with an emphasis on translation of these observations to therapies targeting Tregs in several pathologies. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  AKT; Foxp3; PI3K; regulatory T cell

Year:  2018        PMID: 29357116     DOI: 10.1002/JLB.2MIR0817-349R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  55 in total

1.  Effect of Sishen Pill on Memory T Cells From Experimental Colitis Induced by Dextran Sulfate Sodium.

Authors:  Wei Ge; Hai-Yan Wang; Hai-Mei Zhao; Xue-Ke Liu; You-Bao Zhong; Jian Long; Zheng-Yun Zuo; Duan-Yong Liu
Journal:  Front Pharmacol       Date:  2020-07-02       Impact factor: 5.810

2.  Sirtuin4 suppresses the anti-neuroinflammatory activity of infiltrating regulatory T cells in the traumatically injured spinal cord.

Authors:  Wenping Lin; Wenkai Chen; Weifeng Liu; Zhengquan Xu; Liqun Zhang
Journal:  Immunology       Date:  2019-10-13       Impact factor: 7.397

3.  Higher expression of cation transport regulator-like protein 1 (CHAC1) predicts of poor outcomes in uveal melanoma (UM) patients.

Authors:  Yanchen Liu; Mengyun Li; Danping Shi; Yuguang Zhu
Journal:  Int Ophthalmol       Date:  2019-06-03       Impact factor: 2.031

4.  Cabazitaxel suppresses the proliferation and promotes the apoptosis and radiosensitivity of castration-resistant prostate cancer cells by inhibiting PI3K/AKT pathway.

Authors:  Zheng Xu; Luwei Xu; Yuzheng Ge; Hongbin Sun; Jiageng Zhu; Quanliang Dou; Ruipeng Jia
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

5.  Different MicroRNA profiles in Peripheral Blood mononuclear cells from patients with initial-onset and recurrent vogt-Koyanagi-Harada Disease.

Authors:  Kailei Guo; Baiyi Li; Fuhua Yang; Mi Zhang; Guixia Zhao; Xiaomin Zhang
Journal:  Mol Biol Rep       Date:  2022-08-21       Impact factor: 2.742

6.  Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer.

Authors:  Lin Shi; Weiliang Zhu; Yuanyuan Huang; Lin Zhuo; Siyun Wang; Shaobing Chen; Bei Zhang; Bin Ke
Journal:  Clin Transl Med       Date:  2022-07

Review 7.  Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.

Authors:  David H Munn; Madhav D Sharma; Theodore S Johnson
Journal:  Cancer Res       Date:  2018-09-04       Impact factor: 12.701

8.  Berberine attenuated the cytotoxicity induced by t-BHP via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells.

Authors:  Zhengmao Li; Ting Jiang; Qi Lu; Ke Xu; Jianping He; Lei Xie; Zaifeng Chen; Zhilong Zheng; Luxia Ye; Kebin Xu; Hongyu Zhang; Aiping Hu
Journal:  Cell Mol Neurobiol       Date:  2019-12-11       Impact factor: 5.046

9.  miR‑130b regulates PTEN to activate the PI3K/Akt signaling pathway and attenuate oxidative stress‑induced injury in diabetic encephalopathy.

Authors:  Yonghua Lei; Ming Yang; Hong Li; Rongjuan Xu; Junbao Liu
Journal:  Int J Mol Med       Date:  2021-06-03       Impact factor: 4.101

10.  Low molecular weight-PAHs induced inflammation in A549 cells by activating PI3K/AKT and NF-κB signaling pathways.

Authors:  Huizhen Guo; Yushan Huang; Huiling Wang; Zhewen Zhang; Chengyun Li; Fengjing Hu; Wenwen Zhang; Yang Liu; Yong Zeng; Junling Wang
Journal:  Toxicol Res (Camb)       Date:  2021-01-25       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.